Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study

Histone deacetylase inhibitors are members of a class of epigenetic drugs that have proven activity in T-cell malignancies, but little is known about their efficacy in B-cell lymphomas. Abexinostat is an orally available hydroxamate-containing histone deacetylase inhibitor that differs from approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Ribrag, Vincent, Kim, Won Seog, Bouabdallah, Reda, Lim, Soon Thye, Coiffier, Bertrand, Illes, Arpad, Lemieux, Bernard, Dyer, Martin J. S., Offner, Fritz, Felloussi, Zakia, Kloos, Ioana, Luan, Ying, Vezan, Remus, Graef, Thorsten, Morschhauser, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477609/
https://www.ncbi.nlm.nih.gov/pubmed/28126962
http://dx.doi.org/10.3324/haematol.2016.154377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477609/
https://www.ncbi.nlm.nih.gov/pubmed/28126962
http://dx.doi.org/10.3324/haematol.2016.154377

Ejemplares similares